Let Activefol.io Invest in ABT on Your Behalf.

Stock Detail Header
  • Active Investing
  • Personalized Strategy
  • Low Monthly Fees
Get Started
Stock Details
  • PRICE$81.91
  • PRICE CHANGE-$2.46
  • % CHANGE-2.92%


Course of Action


Sentiment (10 days)

  •  Strong Buy
  •  Buy
  •  Hold
  •  Sell
  •  Strong Sell


  • BullishBullish
  • BearishBearish
  • SentimentSentiment
  • BarPrice

What is Activefol.io?

Activefol.io, our automated portfolio management platform, is designed to manage individual portfolios using the latest technology. Its proprietary system is designed to screens, monitors and invest in elite stocks like "ABBOTT LABORATORIES (ABT)" using is unique Artificial Intelligence signals. It is designed to augment investors profit potential.

Activefol.io produces short-term trades which makes it an ideal tool for investing in tax-deferred accounts such as IRAs and Roth IRAs. If also works great in individual and joint taxable accounts. Just be aware that Activefol.io produces short-term investments that can be taxed at different rates than long-term investments. Make sure you understand your tax situation before using Activefol.io.

Using Activefol.io is easy. It connects to your account located at one of our supported Broker / Dealers. Our current Partners are offering brokerage services in the United States only. You will need a minimum of $25,000 deposited in your account, enable your margin to allow continuous investing to take place. Once enabled, Activefol.io will start working on your behalf.


There are clear benefits associated with using an automated portfolio management system such as Activefol.io to help you reach your financial goals. Activefol.io simplifies stock investing down to a few easy steps. It invests for you, using your personalized strategy, while you attend more important life events.

Using Activefol.io feels like having a professional Portfolio Manager working for you to help you reach your financial goals.

Activefol.io actively invests in the most positive components of the S&P 500® on your behalf. Its Artificial Intelligence signal takes into account emotional and rational indicators to provide key intelligence, 24/7. It 'trades on the news' taking advantage of price changes and trends by listening to market changes.

Activefol.iois one of the first automated management platforms to take advantage of Government grade listening technology. It consumes market data and other specialized data feeds natively to produce a dynamic picture of the market.

Try Activefol.io today!

You can test Activefol.io in simulation mode, risk free, Stock Circles today.

Get started now - and see where active automated trading can take you.

Disclaimer: Past performance may not be indicative of future results. ACTIVEFOL.IOg, like other investment methods, rely on favorable market conditions to provide positive returns.


Abbott Laboratories (NYSE:ABT) Updates FY18 Earnings Guidance

Aug 3rd, 2018 - Abbott Laboratories (NYSE:ABT) updated its FY18 earnings guidance on Wednesday. The company provided earnings per share (EPS) guidance of $2.85-2.91 for the period, compared to the Thomson Reuters consensus estimate of $2.86. Abbott Laboratories also updated its Q3 guidance to $0.73-0.75 EPS.

A number of research analysts have weighed in on the company. Zacks Investment Research lowered Abbott Laboratories from a buy rating to a hold rating in a research note on Tuesday. Stifel Nicolaus increased their target price on Abbott Laboratories from $71.00 to $72.00 and gave the stock a buy rating in a research report on Thursday, July 19th. Royal Bank of Canada reaffirmed a buy rating and issued a $70.00 target price on shares of Abbott Laboratories in a research report on Thursday, July 19th. Sanford C. Bernstein initiated coverage on Abbott Laboratories in a research report on Wednesday, June 27th. They issued an outperform rating and a $73.00 target price on the stock. Finally, BTIG Research reaffirmed a hold rating on shares of Abbott Laboratories in a research report on Sunday, April 22nd. Five research analysts have rated the stock with a hold rating and sixteen have assigned a buy rating to the company. The company presently has a consensus rating of Buy and an average price target of $69.76.

Get Started today! - Risk Free

Investors who like ABBOTT LABORATORIES (ABT) also like

Most Talked About Stocks on Stock Circles

Stock Bubbles